Multivariate analysis of risk for death
Variables . | RR of death (95% CI) . | P . |
|---|---|---|
| Disease type and use of TBI | .001† | |
| NHL with TBI, n = 37 | 1.00 | - |
| NHL no TBI, n = 42 | 2.11 (1.19-3.77) | .01 |
| HL with TBI, n = 8* | 0.98 (0.33-2.85) | .96 |
| HL no TBI, n = 27 | 1.44 (0.76-2.76) | .26 |
| Karnofsky performance score at transplantation | - | |
| 90%-100%, n = 64 | 1.00 | - |
| 80% or less, n = 50 | 1.76 (1.10-2.82) | .02 |
| Disease status before second transplantation | .006† | |
| Complete remission, n = 24 | 1.00 | - |
| Relapse/primary induction failure, chemosensitive, n = 39 | 2.76 (1.27-5.96) | .01 |
| Relapse/primary induction failure, chemoresistant, n = 23 | 3.95 (1.70-9.15) | .001 |
| Relapse/primary induction failure, untreated, n = 28 | 3.74 (1.67-8.41) | .001 |
| Donor type | .004‡ | |
| HLA-identical sibling, n = 70 | 1.00 | - |
| Haploidentical sibling, n = 17 | 2.40 (1.24-4.66) | .009 |
| Unrelated, n = 27 | 2.14 (1.24-3.68) | .006 |
Variables . | RR of death (95% CI) . | P . |
|---|---|---|
| Disease type and use of TBI | .001† | |
| NHL with TBI, n = 37 | 1.00 | - |
| NHL no TBI, n = 42 | 2.11 (1.19-3.77) | .01 |
| HL with TBI, n = 8* | 0.98 (0.33-2.85) | .96 |
| HL no TBI, n = 27 | 1.44 (0.76-2.76) | .26 |
| Karnofsky performance score at transplantation | - | |
| 90%-100%, n = 64 | 1.00 | - |
| 80% or less, n = 50 | 1.76 (1.10-2.82) | .02 |
| Disease status before second transplantation | .006† | |
| Complete remission, n = 24 | 1.00 | - |
| Relapse/primary induction failure, chemosensitive, n = 39 | 2.76 (1.27-5.96) | .01 |
| Relapse/primary induction failure, chemoresistant, n = 23 | 3.95 (1.70-9.15) | .001 |
| Relapse/primary induction failure, untreated, n = 28 | 3.74 (1.67-8.41) | .001 |
| Donor type | .004‡ | |
| HLA-identical sibling, n = 70 | 1.00 | - |
| Haploidentical sibling, n = 17 | 2.40 (1.24-4.66) | .009 |
| Unrelated, n = 27 | 2.14 (1.24-3.68) | .006 |